Jafron Biomedical Co.,Ltd. (300529.SZ)
CNY 30.04
(-0.07%)
CNY 30.04
(-0.07%)
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2023 | 689.28 Million CNY | -39.55% |
| 2022 | 1.13 Billion CNY | -23.39% |
| 2021 | 1.48 Billion CNY | 40.2% |
| 2020 | 1.07 Billion CNY | 49.74% |
| 2019 | 702.32 Million CNY | 41.56% |
| 2018 | 495.45 Million CNY | 59.86% |
| 2017 | 310.53 Million CNY | 20.07% |
| 2016 | 258.33 Million CNY | 8.69% |
| 2015 | 237.08 Million CNY | 35.31% |
| 2014 | 174.2 Million CNY | 22.52% |
| 2013 | 143.05 Million CNY | 29.39% |
| 2012 | 110.67 Million CNY | 32.17% |
| 2011 | 84.28 Million CNY | 0.0% |
| Year | EBITDA | EBITDA Growth |
|---|---|---|
| 2024 Q1 | 355.27 Million CNY | 430.09% |
| 2024 Q3 | 309.75 Million CNY | -16.3% |
| 2024 Q2 | 346.35 Million CNY | 3.87% |
| 2023 FY | - CNY | -39.55% |
| 2023 Q4 | 57.76 Million CNY | -69.03% |
| 2023 Q3 | 186.55 Million CNY | 74.99% |
| 2023 Q1 | 237.65 Million CNY | 1207.08% |
| 2023 Q2 | 106.6 Million CNY | -55.14% |
| 2022 Q3 | 144.12 Million CNY | -70.67% |
| 2022 FY | - CNY | -23.39% |
| 2022 Q2 | 491.43 Million CNY | 22.0% |
| 2022 Q1 | 402.8 Million CNY | 0.3% |
| 2022 Q4 | 18.18 Million CNY | -87.38% |
| 2021 FY | - CNY | 40.2% |
| 2021 Q1 | 331.7 Million CNY | 21.02% |
| 2021 Q4 | 401.58 Million CNY | 40.52% |
| 2021 Q3 | 285.78 Million CNY | -29.01% |
| 2021 Q2 | 402.56 Million CNY | 21.36% |
| 2020 Q4 | 274.08 Million CNY | 24.91% |
| 2020 Q3 | 219.42 Million CNY | -27.76% |
| 2020 FY | - CNY | 49.74% |
| 2020 Q1 | 218.59 Million CNY | 8.59% |
| 2020 Q2 | 303.76 Million CNY | 38.96% |
| 2019 Q1 | 145.04 Million CNY | -7.67% |
| 2019 Q2 | 218.05 Million CNY | 50.34% |
| 2019 Q4 | 201.29 Million CNY | 61.12% |
| 2019 FY | - CNY | 41.56% |
| 2019 Q3 | 124.93 Million CNY | -42.7% |
| 2018 Q4 | 157.09 Million CNY | 50.01% |
| 2018 Q2 | 152.11 Million CNY | 55.11% |
| 2018 Q1 | 98.06 Million CNY | 19.6% |
| 2018 FY | - CNY | 59.86% |
| 2018 Q3 | 104.72 Million CNY | -31.15% |
| 2017 Q4 | 81.99 Million CNY | 32.93% |
| 2017 Q1 | 66.5 Million CNY | -22.26% |
| 2017 FY | - CNY | 20.07% |
| 2017 Q2 | 84.23 Million CNY | 26.67% |
| 2017 Q3 | 61.68 Million CNY | -26.78% |
| 2016 Q2 | 60.2 Million CNY | 1.35% |
| 2016 FY | - CNY | 8.69% |
| 2016 Q4 | 85.55 Million CNY | 100.81% |
| 2016 Q3 | 42.6 Million CNY | -29.23% |
| 2016 Q1 | 59.39 Million CNY | -16.53% |
| 2015 FY | - CNY | 35.31% |
| 2015 Q4 | 71.16 Million CNY | 41.79% |
| 2015 Q3 | 50.18 Million CNY | -12.84% |
| 2015 Q2 | 57.58 Million CNY | 8.86% |
| 2015 Q1 | 52.89 Million CNY | 0.0% |
| 2014 FY | - CNY | 22.52% |
| 2013 FY | - CNY | 29.39% |
| 2012 FY | - CNY | 32.17% |
| 2011 FY | - CNY | 0.0% |